SCHEMBL680637

SCHEMBL680637

CC(C)(C)OC(=O)Nc1ccc(-c2cc3c(cnn3C3CCCCO3)cc2OCc2ccccc2)cn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
PTGER1 P34995 2/20 0.39
CYP2C9 P11712 1/20 0.39
GRIN2B Q13224 1/20 0.39
BCL2 P10415 1/20 0.39
ATR Q13535 4/20 0.38
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
CDK9 P50750 1/20 0.36
PRMT5 O14744 3/20 0.36
MAPK1 P28482 1/20 0.35
SCD O00767 1/20 0.35
PIK3CD O00329 1/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680337 0.90 RXRA (0.50) RXRARXRBRXRGPTGER1ATR
SCHEMBL680219 0.84 RXRA (0.50) RXRARXRBRXRGPTGER1ATR
SCHEMBL679445 0.83 RXRA (0.50) RXRARXRBRXRGATRCYP11B1
SCHEMBL680099 0.76 RXRA (0.49) RXRARXRBRXRGPTGER1ATR
SCHEMBL680848 0.75 RXRA (0.53) RXRARXRBRXRGATRGSK3B
SCHEMBL28690453 0.75 RXRA (0.43) RXRARXRBRXRGCDK9CYP4F2
SCHEMBL1141454 0.73 RXRA (0.40) RXRARXRBRXRGATRPRMT5
SCHEMBL1141462 0.73 RXRA (0.39) RXRARXRBRXRGATRPRMT5
SCHEMBL680086 0.73 RXRA (0.43) RXRARXRBRXRGGRIN2BPIK3CD
SCHEMBL680602 0.73 ATR (0.47) RXRARXRBRXRGATRCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.